Glp-1 Therapy For Specialized Renal Renal Function

More recently, in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, the first dedicated CKD study with a GLP-1 receptor agonist, semaglutide 1 mg subcutaneously once weekly reduced clinically important kidney outcomes and reduced loss of kidney function, major adverse cardiovascular events, all-cause mortality, and heart failure events in patients with type 2 diabetes with ...

The primary outcome was the composite of kidney failure (defined as estimated glomerular filtration rate <15 mL/min/1.73 m 2) or dialysis requirement, worsening of renal function and changes in proteinuria. Subgroup analysis was performed based on diabetic status, a (CKD) and individual GLP1-RA drugs.

As we can see from the illustration, Glp-1 Therapy For Specialized Renal Renal Function has many fascinating aspects to explore.

GLP-1 therapy gives you HbA1c reduction and weight loss in the same molecule. For most of my T2D patients, it is now the first line after metformin. Profile 3. The PCOS patient who has tried everything.

Assess the renal function before and after the introduction in the therapeutical scheme of some drugs that could be potentionally nephrotoxic3.